1.
Cureus
; 10(10): e3477, 2018 Oct 22.
Article
in English
| MEDLINE
| ID: mdl-30648028
ABSTRACT
Adalimumab is a recombinant monoclonal antibody to tumor necrosis factor alpha (TNFα) used in the treatment of inflammatory and autoimmune conditions, including ulcerative colitis (UC). Adverse side effects include infection and injection-site cutaneous reactions; however, rare adverse events such as pancytopenia have been recorded. Here we describe a case of pancytopenia and reversible lymphadenopathy related to adalimumab administration in a patient with UC.